文献速递生殖医学妇科

铂类化疗与青少年及年轻成人女性癌症幸存者活产及不孕症的关联

Association of platinum-based chemotherapy with live birth and infertility in female survivors of adolescent and young adult cancer.
PubMed 文献 · Fertil Steril · 2024-02-03

美国行政数据库回顾性队列研究,纳入15-39岁女性乳腺癌、结直肠癌和卵巢癌幸存者,比较接受铂类化疗、未化疗及无癌女性。考虑竞争事件后,化疗组5年活产率3.9%低于未化疗组6.4%,不孕症发生率两组相似(21.8% vs 20.7%)。

要点

  • 铂类化疗组5年活产率为3.9%,低于未化疗组的6.4%。
  • 铂类化疗组5年不孕症发生率为21.8%,与未化疗组的20.7%相似。
  • 竞争事件分析影响铂类化疗效果的估计。

核心结论

  • 接受铂类化疗的癌症幸存者出现轻度增加的不良生育结局。
  • 铂类化疗的估计效果受竞争事件影响,提示该分析方法对最终指导临床生育力保存决策的重要性。

研究设计与样本

  • 回顾性队列研究,使用美国行政数据库。
  • 纳入15-39岁女性乳腺癌、结直肠癌和卵巢癌病例,接受铂类化疗或未化疗,并匹配无癌女性。
  • 化疗组1287例幸存者,未化疗组3192例,无癌组34147例女性,平均年龄33岁。

主要发现

  • 考虑竞争事件后,总体5年活产发生率化疗组为3.9%,未化疗组为6.4%。
  • 活产的调整相对风险:化疗组 vs 未化疗组为0.61(95%CI 0.42-0.82),化疗组 vs 无癌组为0.70(95%CI 0.51-0.93)。
  • 总体5年不孕症发生率化疗组为21.8%,未化疗组为20.7%。
  • 不孕症的调整相对风险:化疗组 vs 未化疗组为1.05(95%CI 0.97-1.15),化疗组 vs 无癌组为1.42(95%CI 1.31-1.53)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of platinum-based chemotherapy on live birth (LB) and infertility after cancer, in order to address a lack of treatment-specific fertility risks for female survivors of adolescent and young adult cancer, which limits counseling on fertility preservation decisions. DESIGN: Retrospective cohort study. SETTING: US administrative database. PATIENTS: We identified incident breast, colorectal, and ovarian cancer cases in females aged 15-39 years who received platinum-based chemotherapy or no chemotherapy and matched them to females without cancer. INTERVENTION: Platinum-based chemotherapy. MAIN OUTCOME MEASURES: We estimated the effect of chemotherapy on the incidence of LB and infertility after cancer, overall, and after accounting for competing events (recurrence, death, and sterilizing surgeries). RESULTS: There were 1,287 survivors in the chemotherapy group, 3,192 in the no chemotherapy group, and 34,147 women in the no cancer group, with a mean age of 33 years. Accounting for competing events, the overall 5-year LB incidence was lower in the chemotherapy group (3.9%) vs. the no chemotherapy group (6.4%). Adjusted relative risks vs. no chemotherapy and no cancer groups were 0.61 (95% confidence interval [CI] 0.42-0.82) and 0.70 (95% CI 0.51-0.93), respectively. The overall 5-year infertility incidence was similar in the chemotherapy group (21.8%) compared with the no chemotherapy group (20.7%). The adjusted relative risks vs. no chemotherapy and no cancer groups were 1.05 (95% CI 0.97-1.15) and 1.42 (95% CI 1.31-1.53), respectively. CONCLUSIONS: Cancer survivors treated with platinum-based chemotherapy experienced modestly increased adverse fertility outcomes. The estimated effects of platinum-based chemotherapy were affected by competing events, suggesting the importance of this analytic approach for interpretations that ultimately inform clinical fertility preservation decisions.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Zhou B, Kwan B, Desai MJ, et al. Association of platinum-based chemotherapy with live birth and infertility in female survivors of adolescent and young adult cancer. Fertil Steril. 2024. PMID: 38316209. doi:10.1016/j.fertnstert.2024.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。